Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice - Wikidata - thesis-toulmin - TriplyDB

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

http://www.wikidata.org/entity/Q33639966

about

Study of camelpox virus pathogenesis in athymic nude mice Modeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.A cutting-edge view on the current state of antiviral drug development.Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Development of ST-246® for Treatment of Poxvirus Infections.Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246.Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.Phospholipase D: enzymology, functionality, and chemical modulation Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Update on new antivirals under development for the treatment of double-stranded DNA virus infections Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.Protective murine and human monoclonal antibodies against eczema vaccinatum

P2860

Q28743156-27A5719A-CFB2-42D6-9E39-0128132F8A49 Q30205740-8588BB76-7A96-4964-8271-3F2590887FBB Q34036018-E5C63716-EBDE-4AAF-BA10-0EA45DD43B0F Q34432037-CE2D1526-AFE7-4BF3-A3AF-3BA5E1283D1D Q34469836-F151CBB0-0F1E-46F6-89FC-54E382694B5F Q34502253-C07D9A69-5726-4867-A73E-691BB60AADB1 Q35110971-A3808703-8E92-4C82-B0FC-B87C2B421D51 Q35152092-DEBF5A41-C04D-40EA-B93E-39BF5493957F Q35260385-9D35E199-5D5D-494D-A0EE-FFCBCA72B045 Q35260533-08994E3D-27C4-4CA3-9137-DEE98E0A9A4C Q35261304-AC1B17C5-7FC3-481C-9275-15FD4A2F637F Q35599714-C7E06518-6797-4903-A0C3-DFCB1B551A95 Q35909727-B22420B4-53F9-4A75-AEEA-181C80549576 Q36130201-81C8489E-FBF9-4B1C-9CF1-3281DB429493 Q36185647-19555433-E3D7-4056-A280-3FADBAFAF815 Q36827391-9BEB8AEC-4015-40A2-9462-9ABA9DA9E55F Q37335688-A0B2852F-2BEC-4159-9DA8-C09FADA05299 Q37539293-90BCE086-0E51-4E38-BCB2-ECAE611D2123 Q37593480-3270F224-F445-4048-9C90-A1E412211428 Q41649964-2618442A-1AF9-4902-8CEA-4BA53F18DBAC Q42638248-BD9D8877-E204-4EEE-9DF2-DFDBD414FD02

P2860

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

http://www.wikidata.org/entity/Q33639966

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@ast

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@en

type

label

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@ast

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@en

prefLabel

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@ast

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@en

P1433

Q33639966-CD4D6F53-76A6-4559-863C-3F4EEFA3ED9F

P1476

Q33639966-B8CBB5DF-5D96-4653-9B39-CCCAC9DAB42E

P2093

Q33639966-0E512F93-1439-48C8-B6D7-2EFD40728CBD

Q33639966-10B7824B-264A-43D3-8C45-FD7F6ABA3184

Q33639966-13050786-328D-45EF-AFE4-77E74029A116

Q33639966-137087E8-D7BF-4A80-BF83-9698A36977DC

Q33639966-26763948-7A13-4794-81C4-773E1CE7BF41

Q33639966-6468E415-40FA-49B8-9F7F-72F013BE7D02

Q33639966-A6F7CEC7-4DD7-4F4B-B854-F1E18D95ED1F

Q33639966-F6A6146A-A1C8-41F1-A3A0-873C2A37FB2A

P2860

Q33639966-04C31594-A065-428C-BABE-D7FF6EB17A2B

Q33639966-14BA6D50-DC01-4671-AEA8-5AE267E947FD

Q33639966-19DFDC62-3479-4AD1-B525-0C4088480AD7

Q33639966-1C88F0FA-0B09-44B1-926F-624ADDEE89CD

Q33639966-33E49CE9-929A-4F20-9F91-9950492443E1

Q33639966-3980EC6B-5D84-4C34-86C7-65BD98EA4C01

Q33639966-39F2B2AF-D04F-4A67-88F8-46AE7A9DA500

Q33639966-449ACC1A-1CFB-4C2A-A216-D8B2CC06552D

Q33639966-49EE23ED-926C-4691-82FC-A5A67A642AF1

Q33639966-57430B55-66EF-4A13-BED5-57C7DA79907E

P304

Q33639966-8758AD37-F941-48E3-915C-8C2A4B2F1F8F

P31

Q33639966-C27D6090-01F7-4507-A973-87971077BF40

P356

Q33639966-0B188A50-63D1-4E30-8171-31466D4F04D7

P407

Q33639966-2060E62D-7C3D-4A32-B846-BCDC46A682B7

P433

Q33639966-3B722511-9173-496C-B234-D7E7E75E4A84

P478

Q33639966-C80B89FB-59DD-416B-84E4-A88759611480

P577

Q33639966-3E307424-7920-4D2C-B47C-2E5F7578E0A5

P5875

Q33639966-EDA3BD9A-192F-4909-8F15-8155FC7ABBE6

P698

Q33639966-E82B7680-DFE9-4DDB-8C93-0DC172384744

P932

Q33639966-76543422-25E0-4126-B026-DFE3702808E0

P356

PNAS.0912134107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

@en

P2093

Aklile Berhanu

http://www.w3.org/2001/XMLSchema#string

David S King

http://www.w3.org/2001/XMLSchema#string

Dennis E Hruby

http://www.w3.org/2001/XMLSchema#string

Douglas W Grosenbach

http://www.w3.org/2001/XMLSchema#string

Kevin F Jones

http://www.w3.org/2001/XMLSchema#string

Robert A Jordan

http://www.w3.org/2001/XMLSchema#string

Stacie Mosier

http://www.w3.org/2001/XMLSchema#string

Tove' C Bolken

http://www.w3.org/2001/XMLSchema#string

P2860

Zoonotic Vaccinia Virus: Clinical and Immunological Characteristics in a Naturally Infected Patient

Smallpox as a Biological Weapon

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997

Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor

New generation smallpox vaccines: a review of preclinical and clinical data.

The looming threat of bioterrorism.

Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection.

Obligatory requirement for antibody in recovery from a primary poxvirus infection

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

P304

838-843

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0912134107

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41040429

http://www.w3.org/2001/XMLSchema#string

P698

20080762

http://www.w3.org/2001/XMLSchema#string

P932

2818887

http://www.w3.org/2001/XMLSchema#string